Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Court-Ordered Access To Experimental PTC Drug Shows Risks Of Patient Outreach

Executive Summary

A judge's decision to order PTC Therapeutics to provide an experimental drug for a teenage boy with Duchenne Muscular Dystrophy highlights the need for caution in communications with patients and their families, particularly in cases of life-threatening disease

You may also be interested in...



FDA Action On Off-Label Tysabri May Signal Policy Shift On Compassionate Use

FDA appears to be setting new policy on when drugs should be available for compassionate use

FDA Action On Off-Label Tysabri May Signal Policy Shift On Compassionate Use

FDA appears to be setting new policy on when drugs should be available for compassionate use

Abigail Alliance Presses For Access To Drugs With Troubled Regulatory Pasts

The Abigail Alliance's legal drama with FDA has ended, but the association continues to engage the agency on a number of products it wants to see offered through expanded access programs

UsernamePublicRestriction

Register

ID1132028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel